Wei‐Sen Lam

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +7

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

Martin Gutierrez, Wei‐Sen Lam, Matthew D. Hellmann et al. · Nature Medicine · 2023 · 42 citations

Medicine, Pathology, Immune Checkpoint Inhibitor +6

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Wei‐Sen Lam, Jenette Creaney, Fred K. Chen et al. · Lung Cancer · 2019 · 29 citations

Malignant Pleural Mesothelioma, Phase Ii Trial, Medicine +7

DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.

Anna K. Nowak, W. Joost Lesterhuis, Brett Hughes et al. · Journal of Clinical Oncology · 2018 · 26 citations

First Line Chemotherapy, Oncology, Cancer Therapeutics +15

Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET

Murali Kesavan, Piyush Grover, Wei‐Sen Lam et al. · Endocrine Related Cancer · 2021 · 26 citations

Surgical Oncology, Long-term Hematologic Toxicity, Pharmacotherapy +22